Table 1.
Ref. | Year | Technique | No. of patients | Morbidity (%) | Mortality (%) | 5-yr disease-free survival (%) | 5-yr overall survival (%) |
Azoulay et al[11] | 2000 | PVE | 10 | 55 | 0 | 21 | 44 |
Tanaka et al[12] | 2000 | PVE | 33 | - | 3 | 33 | 50 |
Wakabayashi et al[13] | 2001 | PVE | 26 | - | 11.5 | 40 | 46 |
Sugawara et al[14] | 2002 | PVE | 66 | - | 0 | 37.9 | 58.9 |
Aoki et al[15] | 2004 | TACE + PVE | 24 | 24 | 0 | 47 | 56 |
Ogata et al[16] | 2006 | TACE + PVE | 18 | 39 | - | 37 | - |
PVE | 18 | 56 | - | 19 | - | ||
Seo et al[17] | 2007 | PVE | 32 | 19 | 0 | 37 | 72 |
Palavecino et al[18] | 2009 | PVE | 21 | 24 | 0 | 56 | 72 |
PVE: Portal vein embolization; TACE: Transcatheter arterial chemoembolization.